<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933762</url>
  </required_header>
  <id_info>
    <org_study_id>CR108231</org_study_id>
    <secondary_id>2016-003040-37</secondary_id>
    <secondary_id>54175446EDI1005</secondary_id>
    <nct_id>NCT02933762</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma</brief_title>
  <official_title>An Exploratory, Single-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Dose Pharmacodynamics Study in Healthy Subjects to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the effects of JNJ-54175446 (dose
      response) on levels of Aβ fragments (Aβ1-42, Aβ1-40, Aβ1-38, Aβ1-37) in plasma and
      cerebrospinal fluid (CSF), the effects of JNJ-54175446 on markers of (neuro)
      inflammation/protection in blood and CSF and the pharmacokinetics of JNJ-54175446 followed by
      single and multiple dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Levels of Aβ Fragments in Plasma</measure>
    <time_frame>Part 1: Up to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Levels of Aβ Fragments in Plasma</measure>
    <time_frame>Part 2: Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Levels of Aβ Fragments in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Part 1: Up to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Levels of Aβ Fragments in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Part 2: Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Markers of (Neuro)Inflammation / Protection in Blood</measure>
    <time_frame>Part 1: Up to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Markers of (Neuro)Inflammation / Protection in Blood</measure>
    <time_frame>Part 2: Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Markers of (Neuro)Inflammation / Protection in CSF</measure>
    <time_frame>Part 1: Up to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effects of JNJ-54175446 (Dose Response) on Markers of (Neuro)Inflammation / Protection in CSF</measure>
    <time_frame>Part 2: Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) After Single- and Multiple-Dose Administration</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin)During Dosing Interval</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Observed Plasma Concentration Just Prior to the Beginning or at the end of a Dosing Interval of any Dose Other Than the First Dose (Ctrough)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Plasma Concentration at Steady State Over the Dosing Interval (Cavg)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Par 2: Day 1, Day 2 to 6, Day 7, Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration, After Single- and Multiple-Dose Administration (Tmax)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration-Time Curve From 0 To t Hours Postdosing (AUCt)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From 0 to 24 Hours Postdosing (AUC24h)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Ratio of the Maximum Plasma Concentration (Peak) to Trough Observed Concentration (Peak/Trough Ratio)</measure>
    <time_frame>Part 1: Day 1 - Day 2; Part 2: Day 1 to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Screening up to follow-up (in part 1 and part 2 [approximately up to 8 weeks])</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive single dose of 30mg JNJ-54175446.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive single dose of 100mg JNJ-54175446.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 300mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive single dose of 300mg JNJ-54175446.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A1 (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive single dose of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A2 (JNJ-54175446 D1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (&lt;=) 600 mg] of JNJ-54175446, to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A3 (JNJ-54175446 D2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young participants will receive a single dose D2 mg (&lt;= 600 mg) of JNJ-54175446, to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort A3 (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young participants will receive a single dose of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B1 (JNJ-54175446 D3 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive multiple dose levels D3 mg (&lt;= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B1 (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive placebo determined based on the results from Cohort A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B2 (JNJ-54175446 D4 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive multiple dose levels D4 mg (&lt;= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B2 (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive placebo determined based on the results from Cohort A1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B3 (JNJ-54175446 D5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive multiple dose levels D5 mg (&lt;= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort B3 (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will receive placebo determined based on the results from Cohort A1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-54175446</intervention_name>
    <description>Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.</description>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])</arm_group_label>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 100mg)</arm_group_label>
    <arm_group_label>Part 1: Cohort A1 (JNJ-54175446 300mg)</arm_group_label>
    <arm_group_label>Part 1: Cohort A2 (JNJ-54175446 D1 mg)</arm_group_label>
    <arm_group_label>Part 1: Cohort A3 (JNJ-54175446 D2 mg)</arm_group_label>
    <arm_group_label>Part 2: Cohort B1 (JNJ-54175446 D3 mg)</arm_group_label>
    <arm_group_label>Part 2: Cohort B2 (JNJ-54175446 D4 mg)</arm_group_label>
    <arm_group_label>Part 2: Cohort B3 (JNJ-54175446 D5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.</description>
    <arm_group_label>Part 1: Cohort A1 (Placebo)</arm_group_label>
    <arm_group_label>Part 1: Cohort A3 (Placebo)</arm_group_label>
    <arm_group_label>Part 2: Cohort B1 (Placebo)</arm_group_label>
    <arm_group_label>Part 2: Cohort B2 (Placebo)</arm_group_label>
    <arm_group_label>Part 2: Cohort B3 (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a body mass index (BMI) between 18 and 32 kilogram (kg)/ meter
             (m)^2, inclusive (BMI = weight/height^2)

          -  Participant must be healthy on the basis of physical examination, medical history,
             vital signs, and 12-lead electrocardiogram (ECG)

        Part 1 and 2 (Elderly Participants):

          -  Healthy male or female participants between 55 and 75 years of age, inclusive

          -  Participant must be healthy on the basis of both physical and neurological examination
             performed at Screening and at admission to the clinical unit

        Part 1 (Young Participants):

        - Healthy male participants between 18 and 45 years of age, inclusive

        Exclusion Criteria:

          -  Participant has a history of or current liver or renal insufficiency; significant
             cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic,
             rheumatologic, psychiatric, or metabolic disturbances, any inflammatory illness or any
             other illness that the Investigator considers should exclude the participant

          -  Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests
             positive for HBsAg or anti-HCV at Screening (per Screening evaluations)

          -  Participant has a history of human immunodeficiency virus (HIV) antibody positive, or
             tests positive for HIV at Screening (per Screening evaluations)

          -  Participant has a history of malignancy within 5 years before Screening

          -  Participant has signs of increased intracranial pressure based on fundoscopy at
             Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

